#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=[0001] The present invention relates to a method for the preparation of a biocompatible titanium oxide coating containing metal ions on an implant wherein the metal ions can be eluted under physiological conditions and are homogenously distributed throughout the coating, as well as to an implant which can be prepared according to the method of the present invention.
1-1	0-1	[	_	_	
1-2	1-5	0001	_	_	
1-3	5-6	]	_	_	
1-4	7-10	The	_	_	
1-5	11-18	present	_	_	
1-6	19-28	invention	_	_	
1-7	29-36	relates	_	_	
1-8	37-39	to	_	_	
1-9	40-41	a	_	_	
1-10	42-48	method	_	_	
1-11	49-52	for	_	_	
1-12	53-56	the	_	_	
1-13	57-68	preparation	_	_	
1-14	69-71	of	_	_	
1-15	72-73	a	_	_	
1-16	74-87	biocompatible	_	_	
1-17	88-96	titanium	_	_	
1-18	97-102	oxide	_	_	
1-19	103-110	coating	_	_	
1-20	111-121	containing	_	_	
1-21	122-127	metal	_	_	
1-22	128-132	ions	_	_	
1-23	133-135	on	_	_	
1-24	136-138	an	_	_	
1-25	139-146	implant	_	_	
1-26	147-154	wherein	_	_	
1-27	155-158	the	_	_	
1-28	159-164	metal	_	_	
1-29	165-169	ions	_	_	
1-30	170-173	can	_	_	
1-31	174-176	be	_	_	
1-32	177-183	eluted	_	_	
1-33	184-189	under	_	_	
1-34	190-203	physiological	_	_	
1-35	204-214	conditions	_	_	
1-36	215-218	and	_	_	
1-37	219-222	are	_	_	
1-38	223-235	homogenously	_	_	
1-39	236-247	distributed	_	_	
1-40	248-258	throughout	_	_	
1-41	259-262	the	_	_	
1-42	263-270	coating	_	_	
1-43	270-271	,	_	_	
1-44	272-274	as	_	_	
1-45	275-279	well	_	_	
1-46	280-282	as	_	_	
1-47	283-285	to	_	_	
1-48	286-288	an	_	_	
1-49	289-296	implant	_	_	
1-50	297-302	which	_	_	
1-51	303-306	can	_	_	
1-52	307-309	be	_	_	
1-53	310-318	prepared	_	_	
1-54	319-328	according	_	_	
1-55	329-331	to	_	_	
1-56	332-335	the	_	_	
1-57	336-342	method	_	_	
1-58	343-345	of	_	_	
1-59	346-349	the	_	_	
1-60	350-357	present	_	_	
1-61	358-367	invention	_	_	
1-62	367-368	.	_	_	

#Text=BACKGROUND OF THE INVENTION AND PRIOR ART
#Text=[0002] Silver or silver-containing coatings for anti-infectious finishing of short-term implants, such as catheters, are conventional methods already used in the clinical field, and the anti-bacterial effect is known from the literature [1-3].
2-1	369-379	BACKGROUND	_	_	
2-2	380-382	OF	_	_	
2-3	383-386	THE	_	_	
2-4	387-396	INVENTION	_	_	
2-5	397-400	AND	_	_	
2-6	401-406	PRIOR	_	_	
2-7	407-410	ART	_	_	
2-8	411-412	[	_	_	
2-9	412-416	0002	_	_	
2-10	416-417	]	_	_	
2-11	418-424	Silver	_	_	
2-12	425-427	or	_	_	
2-13	428-445	silver-containing	_	_	
2-14	446-454	coatings	_	_	
2-15	455-458	for	_	_	
2-16	459-474	anti-infectious	_	_	
2-17	475-484	finishing	_	_	
2-18	485-487	of	_	_	
2-19	488-498	short-term	_	_	
2-20	499-507	implants	_	_	
2-21	507-508	,	_	_	
2-22	509-513	such	_	_	
2-23	514-516	as	_	_	
2-24	517-526	catheters	_	_	
2-25	526-527	,	_	_	
2-26	528-531	are	_	_	
2-27	532-544	conventional	_	_	
2-28	545-552	methods	_	_	
2-29	553-560	already	_	_	
2-30	561-565	used	_	_	
2-31	566-568	in	_	_	
2-32	569-572	the	_	_	
2-33	573-581	clinical	_	_	
2-34	582-587	field	_	_	
2-35	587-588	,	_	_	
2-36	589-592	and	_	_	
2-37	593-596	the	_	_	
2-38	597-611	anti-bacterial	_	_	
2-39	612-618	effect	_	_	
2-40	619-621	is	_	_	
2-41	622-627	known	_	_	
2-42	628-632	from	_	_	
2-43	633-636	the	_	_	
2-44	637-647	literature	_	_	
2-45	648-649	[	_	_	
2-46	649-650	1	_	_	
2-47	650-651	-	_	_	
2-48	651-652	3	_	_	
2-49	652-653	]	_	_	
2-50	653-654	.	_	_	

#Text=Up to now, the anti-bacterial effect of copper or copper ions, respectively, has been examined mainly using metallic films, i.e. pure copper surfaces [4].
3-1	655-657	Up	_	_	
3-2	658-660	to	_	_	
3-3	661-664	now	_	_	
3-4	664-665	,	_	_	
3-5	666-669	the	_	_	
3-6	670-684	anti-bacterial	_	_	
3-7	685-691	effect	_	_	
3-8	692-694	of	_	_	
3-9	695-701	copper	_	_	
3-10	702-704	or	_	_	
3-11	705-711	copper	_	_	
3-12	712-716	ions	_	_	
3-13	716-717	,	_	_	
3-14	718-730	respectively	_	_	
3-15	730-731	,	_	_	
3-16	732-735	has	_	_	
3-17	736-740	been	_	_	
3-18	741-749	examined	_	_	
3-19	750-756	mainly	_	_	
3-20	757-762	using	_	_	
3-21	763-771	metallic	_	_	
3-22	772-777	films	_	_	
3-23	777-778	,	_	_	
3-24	779-782	i.e	_	_	
3-25	782-783	.	_	_	
3-26	784-788	pure	_	_	
3-27	789-795	copper	_	_	
3-28	796-804	surfaces	_	_	
3-29	805-806	[	_	_	
3-30	806-807	4	_	_	
3-31	807-808	]	_	_	
3-32	808-809	.	_	_	

#Text=A use of elementary copper as an admixture has been described for an anti-bacterial wall paint [5].
4-1	810-811	A	_	_	
4-2	812-815	use	_	_	
4-3	816-818	of	_	_	
4-4	819-829	elementary	_	_	
4-5	830-836	copper	_	_	
4-6	837-839	as	_	_	
4-7	840-842	an	_	_	
4-8	843-852	admixture	_	_	
4-9	853-856	has	_	_	
4-10	857-861	been	_	_	
4-11	862-871	described	_	_	
4-12	872-875	for	_	_	
4-13	876-878	an	_	_	
4-14	879-893	anti-bacterial	_	_	
4-15	894-898	wall	_	_	
4-16	899-904	paint	_	_	
4-17	905-906	[	_	_	
4-18	906-907	5	_	_	
4-19	907-908	]	_	_	
4-20	908-909	.	_	_	

#Text=The elution of copper ions from copper-thiomolybdate complexes into the blood of rats has been described by Komatsu, et al. [6].
5-1	910-913	The	_	_	
5-2	914-921	elution	_	_	
5-3	922-924	of	_	_	
5-4	925-931	copper	_	_	
5-5	932-936	ions	_	_	
5-6	937-941	from	_	_	
5-7	942-962	copper-thiomolybdate	_	_	
5-8	963-972	complexes	_	_	
5-9	973-977	into	_	_	
5-10	978-981	the	_	_	
5-11	982-987	blood	_	_	
5-12	988-990	of	_	_	
5-13	991-995	rats	_	_	
5-14	996-999	has	_	_	
5-15	1000-1004	been	_	_	
5-16	1005-1014	described	_	_	
5-17	1015-1017	by	_	_	
5-18	1018-1025	Komatsu	_	_	
5-19	1025-1026	,	_	_	
5-20	1027-1029	et	_	_	
5-21	1030-1032	al	_	_	
5-22	1032-1033	.	_	_	
5-23	1034-1035	[	_	_	
5-24	1035-1036	6	_	_	
5-25	1036-1037	]	_	_	
5-26	1037-1038	.	_	_	

#Text=Copper-containing titanium oxide layers obtained by thermal oxidation of a copper-containing titanium alloy are disclosed in the Japanese Patent laid-open Nos.
6-1	1039-1056	Copper-containing	*[1]	8-1[2_1]	
6-2	1057-1065	titanium	*[1]	_	
6-3	1066-1071	oxide	*[1]	_	
6-4	1072-1078	layers	*[1]	_	
6-5	1079-1087	obtained	*[1]	_	
6-6	1088-1090	by	*[1]	_	
6-7	1091-1098	thermal	*[1]	_	
6-8	1099-1108	oxidation	*[1]	_	
6-9	1109-1111	of	*[1]	_	
6-10	1112-1113	a	*[1]	_	
6-11	1114-1131	copper-containing	*[1]	_	
6-12	1132-1140	titanium	*[1]	_	
6-13	1141-1146	alloy	*[1]	_	
6-14	1147-1150	are	*[1]	_	
6-15	1151-1160	disclosed	*[1]	_	
6-16	1161-1163	in	*[1]	_	
6-17	1164-1167	the	*[1]	_	
6-18	1168-1176	Japanese	*[1]	_	
6-19	1177-1183	Patent	*[1]	_	
6-20	1184-1193	laid-open	*[1]	_	
6-21	1194-1197	Nos	*[1]	_	
6-22	1197-1198	.	*[1]	_	

#Text=JP9118987 and JP9249981.
7-1	1199-1208	JP9118987	*[1]	_	
7-2	1209-1212	and	*[1]	_	
7-3	1213-1222	JP9249981	*[1]	_	
7-4	1222-1223	.	*[1]	_	

#Text=This method does not comprise a true coating procedure or coatings, respectively, however, merely the surface of copper-containing titanium alloys is altered by means of an acid treatment.
8-1	1224-1228	This	*[2]	_	
8-2	1229-1235	method	*[2]	_	
8-3	1236-1240	does	_	_	
8-4	1241-1244	not	_	_	
8-5	1245-1253	comprise	_	_	
8-6	1254-1255	a	_	_	
8-7	1256-1260	true	_	_	
8-8	1261-1268	coating	_	_	
8-9	1269-1278	procedure	_	_	
8-10	1279-1281	or	_	_	
8-11	1282-1290	coatings	_	_	
8-12	1290-1291	,	_	_	
8-13	1292-1304	respectively	_	_	
8-14	1304-1305	,	_	_	
8-15	1306-1313	however	_	_	
8-16	1313-1314	,	_	_	
8-17	1315-1321	merely	_	_	
8-18	1322-1325	the	_	_	
8-19	1326-1333	surface	_	_	
8-20	1334-1336	of	_	_	
8-21	1337-1354	copper-containing	_	_	
8-22	1355-1363	titanium	_	_	
8-23	1364-1370	alloys	_	_	
8-24	1371-1373	is	_	_	
8-25	1374-1381	altered	_	_	
8-26	1382-1384	by	_	_	
8-27	1385-1390	means	_	_	
8-28	1391-1393	of	_	_	
8-29	1394-1396	an	_	_	
8-30	1397-1401	acid	_	_	
8-31	1402-1411	treatment	_	_	
8-32	1411-1412	.	_	_	

#Text=The French Patent Application FR2780417 describes a similar procedure but wherein the surface of the treated alloy is treated with an oxidizing mineral acid prior to oxidation to form a surface oxide layer.
9-1	1413-1416	The	_	_	
9-2	1417-1423	French	_	_	
9-3	1424-1430	Patent	_	_	
9-4	1431-1442	Application	_	_	
9-5	1443-1452	FR2780417	_	_	
9-6	1453-1462	describes	_	_	
9-7	1463-1464	a	_	_	
9-8	1465-1472	similar	_	_	
9-9	1473-1482	procedure	_	_	
9-10	1483-1486	but	_	_	
9-11	1487-1494	wherein	_	_	
9-12	1495-1498	the	_	_	
9-13	1499-1506	surface	_	_	
9-14	1507-1509	of	_	_	
9-15	1510-1513	the	_	_	
9-16	1514-1521	treated	_	_	
9-17	1522-1527	alloy	_	_	
9-18	1528-1530	is	_	_	
9-19	1531-1538	treated	_	_	
9-20	1539-1543	with	_	_	
9-21	1544-1546	an	_	_	
9-22	1547-1556	oxidizing	_	_	
9-23	1557-1564	mineral	_	_	
9-24	1565-1569	acid	_	_	
9-25	1570-1575	prior	_	_	
9-26	1576-1578	to	_	_	
9-27	1579-1588	oxidation	_	_	
9-28	1589-1591	to	_	_	
9-29	1592-1596	form	_	_	
9-30	1597-1598	a	_	_	
9-31	1599-1606	surface	_	_	
9-32	1607-1612	oxide	_	_	
9-33	1613-1618	layer	_	_	
9-34	1618-1619	.	_	_	

#Text=The preparation of biocompatible titanium oxide coatings from nanosuspensions, so-called sols, is known for example from [7] and [8].
#Text=[0003] In a clinical environment bacterial contaminations are a latent an unavoidable danger, particular in the surgical area, e.g. during operative interventions at a patient.
10-1	1620-1623	The	_	_	
10-2	1624-1635	preparation	_	_	
10-3	1636-1638	of	_	_	
10-4	1639-1652	biocompatible	_	_	
10-5	1653-1661	titanium	_	_	
10-6	1662-1667	oxide	_	_	
10-7	1668-1676	coatings	_	_	
10-8	1677-1681	from	_	_	
10-9	1682-1697	nanosuspensions	_	_	
10-10	1697-1698	,	_	_	
10-11	1699-1708	so-called	_	_	
10-12	1709-1713	sols	_	_	
10-13	1713-1714	,	_	_	
10-14	1715-1717	is	_	_	
10-15	1718-1723	known	_	_	
10-16	1724-1727	for	_	_	
10-17	1728-1735	example	_	_	
10-18	1736-1740	from	_	_	
10-19	1741-1742	[	_	_	
10-20	1742-1743	7	_	_	
10-21	1743-1744	]	_	_	
10-22	1745-1748	and	_	_	
10-23	1749-1750	[	_	_	
10-24	1750-1751	8	_	_	
10-25	1751-1752	]	_	_	
10-26	1752-1753	.	_	_	
10-27	1754-1755	[	_	_	
10-28	1755-1759	0003	_	_	
10-29	1759-1760	]	_	_	
10-30	1761-1763	In	_	_	
10-31	1764-1765	a	_	_	
10-32	1766-1774	clinical	_	_	
10-33	1775-1786	environment	_	_	
10-34	1787-1796	bacterial	_	_	
10-35	1797-1811	contaminations	_	_	
10-36	1812-1815	are	_	_	
10-37	1816-1817	a	_	_	
10-38	1818-1824	latent	_	_	
10-39	1825-1827	an	_	_	
10-40	1828-1839	unavoidable	_	_	
10-41	1840-1846	danger	_	_	
10-42	1846-1847	,	_	_	
10-43	1848-1858	particular	_	_	
10-44	1859-1861	in	_	_	
10-45	1862-1865	the	_	_	
10-46	1866-1874	surgical	_	_	
10-47	1875-1879	area	_	_	
10-48	1879-1880	,	_	_	
10-49	1881-1884	e.g	_	_	
10-50	1884-1885	.	_	_	
10-51	1886-1892	during	_	_	
10-52	1893-1902	operative	_	_	
10-53	1903-1916	interventions	_	_	
10-54	1917-1919	at	_	_	
10-55	1920-1921	a	_	_	
10-56	1922-1929	patient	_	_	
10-57	1929-1930	.	_	_	

#Text=Primarily due to the introduction of foreign objects (implants such as catheters, osteosynthesis plates, endoprostheses, etc.) a process occurs immediately following implantation which is called in the literature a "race for the surface" [11].
11-1	1931-1940	Primarily	_	_	
11-2	1941-1944	due	_	_	
11-3	1945-1947	to	_	_	
11-4	1948-1951	the	_	_	
11-5	1952-1964	introduction	_	_	
11-6	1965-1967	of	_	_	
11-7	1968-1975	foreign	_	_	
11-8	1976-1983	objects	_	_	
11-9	1984-1985	(	_	_	
11-10	1985-1993	implants	_	_	
11-11	1994-1998	such	_	_	
11-12	1999-2001	as	_	_	
11-13	2002-2011	catheters	_	_	
11-14	2011-2012	,	_	_	
11-15	2013-2027	osteosynthesis	_	_	
11-16	2028-2034	plates	_	_	
11-17	2034-2035	,	_	_	
11-18	2036-2050	endoprostheses	_	_	
11-19	2050-2051	,	_	_	
11-20	2052-2055	etc	_	_	
11-21	2055-2056	.	_	_	
11-22	2056-2057	)	_	_	
11-23	2058-2059	a	_	_	
11-24	2060-2067	process	_	_	
11-25	2068-2074	occurs	_	_	
11-26	2075-2086	immediately	_	_	
11-27	2087-2096	following	_	_	
11-28	2097-2109	implantation	_	_	
11-29	2110-2115	which	_	_	
11-30	2116-2118	is	_	_	
11-31	2119-2125	called	_	_	
11-32	2126-2128	in	_	_	
11-33	2129-2132	the	_	_	
11-34	2133-2143	literature	_	_	
11-35	2144-2145	a	_	_	
11-36	2146-2147	"	_	_	
11-37	2147-2151	race	_	_	
11-38	2152-2155	for	_	_	
11-39	2156-2159	the	_	_	
11-40	2160-2167	surface	_	_	
11-41	2167-2168	"	_	_	
11-42	2169-2170	[	_	_	
11-43	2170-2172	11	_	_	
11-44	2172-2173	]	_	_	
11-45	2173-2174	.	_	_	

#Text=This refers to a competition between the body's own cells and the microorganisms introduced during the operation to populate the initially sterile surfaces of the implant.
12-1	2175-2179	This	_	_	
12-2	2180-2186	refers	_	_	
12-3	2187-2189	to	_	_	
12-4	2190-2191	a	_	_	
12-5	2192-2203	competition	_	_	
12-6	2204-2211	between	_	_	
12-7	2212-2215	the	_	_	
12-8	2216-2222	body's	_	_	
12-9	2223-2226	own	_	_	
12-10	2227-2232	cells	_	_	
12-11	2233-2236	and	_	_	
12-12	2237-2240	the	_	_	
12-13	2241-2255	microorganisms	_	_	
12-14	2256-2266	introduced	_	_	
12-15	2267-2273	during	_	_	
12-16	2274-2277	the	_	_	
12-17	2278-2287	operation	_	_	
12-18	2288-2290	to	_	_	
12-19	2291-2299	populate	_	_	
12-20	2300-2303	the	_	_	
12-21	2304-2313	initially	_	_	
12-22	2314-2321	sterile	_	_	
12-23	2322-2330	surfaces	_	_	
12-24	2331-2333	of	_	_	
12-25	2334-2337	the	_	_	
12-26	2338-2345	implant	_	_	
12-27	2345-2346	.	_	_	

#Text=If the implant surface is initially colonized excessively by bacterial cells and a manifest infection occurs the immune mechanisms of the human body are induced, and the possibility arises that the implant is rejected.
13-1	2347-2349	If	_	_	
13-2	2350-2353	the	_	_	
13-3	2354-2361	implant	_	_	
13-4	2362-2369	surface	_	_	
13-5	2370-2372	is	_	_	
13-6	2373-2382	initially	_	_	
13-7	2383-2392	colonized	_	_	
13-8	2393-2404	excessively	_	_	
13-9	2405-2407	by	_	_	
13-10	2408-2417	bacterial	_	_	
13-11	2418-2423	cells	_	_	
13-12	2424-2427	and	_	_	
13-13	2428-2429	a	_	_	
13-14	2430-2438	manifest	_	_	
13-15	2439-2448	infection	_	_	
13-16	2449-2455	occurs	_	_	
13-17	2456-2459	the	_	_	
13-18	2460-2466	immune	_	_	
13-19	2467-2477	mechanisms	_	_	
13-20	2478-2480	of	_	_	
13-21	2481-2484	the	_	_	
13-22	2485-2490	human	_	_	
13-23	2491-2495	body	_	_	
13-24	2496-2499	are	_	_	
13-25	2500-2507	induced	_	_	
13-26	2507-2508	,	_	_	
13-27	2509-2512	and	_	_	
13-28	2513-2516	the	_	_	
13-29	2517-2528	possibility	_	_	
13-30	2529-2535	arises	_	_	
13-31	2536-2540	that	_	_	
13-32	2541-2544	the	_	_	
13-33	2545-2552	implant	_	_	
13-34	2553-2555	is	_	_	
13-35	2556-2564	rejected	_	_	
13-36	2564-2565	.	_	_	

#Text=In most cases, implants colonized by bacteria must be removed to treat the infection since even high concentrations of effective antibiotics cannot achieved a complete eradication of adhering bacteria [12, 13].
14-1	2566-2568	In	_	_	
14-2	2569-2573	most	_	_	
14-3	2574-2579	cases	_	_	
14-4	2579-2580	,	_	_	
14-5	2581-2589	implants	_	_	
14-6	2590-2599	colonized	_	_	
14-7	2600-2602	by	_	_	
14-8	2603-2611	bacteria	_	_	
14-9	2612-2616	must	_	_	
14-10	2617-2619	be	_	_	
14-11	2620-2627	removed	_	_	
14-12	2628-2630	to	_	_	
14-13	2631-2636	treat	_	_	
14-14	2637-2640	the	_	_	
14-15	2641-2650	infection	_	_	
14-16	2651-2656	since	_	_	
14-17	2657-2661	even	_	_	
14-18	2662-2666	high	_	_	
14-19	2667-2681	concentrations	_	_	
14-20	2682-2684	of	_	_	
14-21	2685-2694	effective	_	_	
14-22	2695-2706	antibiotics	_	_	
14-23	2707-2713	cannot	_	_	
14-24	2714-2722	achieved	_	_	
14-25	2723-2724	a	_	_	
14-26	2725-2733	complete	_	_	
14-27	2734-2745	eradication	_	_	
14-28	2746-2748	of	_	_	
14-29	2749-2757	adhering	_	_	
14-30	2758-2766	bacteria	_	_	
14-31	2767-2768	[	_	_	
14-32	2768-2770	12	_	_	
14-33	2770-2771	,	_	_	
14-34	2772-2774	13	_	_	
14-35	2774-2775	]	_	_	
14-36	2775-2776	.	_	_	

#Text=If the implant surfaces are devised in a highly toxic manner, however, colonization by the body's own cells required for integration of the implant is inhibited at the same time.
15-1	2777-2779	If	_	_	
15-2	2780-2783	the	_	_	
15-3	2784-2791	implant	_	_	
15-4	2792-2800	surfaces	_	_	
15-5	2801-2804	are	_	_	
15-6	2805-2812	devised	_	_	
15-7	2813-2815	in	_	_	
15-8	2816-2817	a	_	_	
15-9	2818-2824	highly	_	_	
15-10	2825-2830	toxic	_	_	
15-11	2831-2837	manner	_	_	
15-12	2837-2838	,	_	_	
15-13	2839-2846	however	_	_	
15-14	2846-2847	,	_	_	
15-15	2848-2860	colonization	_	_	
15-16	2861-2863	by	_	_	
15-17	2864-2867	the	_	_	
15-18	2868-2874	body's	_	_	
15-19	2875-2878	own	_	_	
15-20	2879-2884	cells	_	_	
15-21	2885-2893	required	_	_	
15-22	2894-2897	for	_	_	
15-23	2898-2909	integration	_	_	
15-24	2910-2912	of	_	_	
15-25	2913-2916	the	_	_	
15-26	2917-2924	implant	_	_	
15-27	2925-2927	is	_	_	
15-28	2928-2937	inhibited	_	_	
15-29	2938-2940	at	_	_	
15-30	2941-2944	the	_	_	
15-31	2945-2949	same	_	_	
15-32	2950-2954	time	_	_	
15-33	2954-2955	.	_	_	

#Text=This effect is especially undesirable for long-term implants, such as hip joint endoprostheses.
16-1	2956-2960	This	_	_	
16-2	2961-2967	effect	_	_	
16-3	2968-2970	is	_	_	
16-4	2971-2981	especially	_	_	
16-5	2982-2993	undesirable	_	_	
16-6	2994-2997	for	_	_	
16-7	2998-3007	long-term	_	_	
16-8	3008-3016	implants	_	_	
16-9	3016-3017	,	_	_	
16-10	3018-3022	such	_	_	
16-11	3023-3025	as	_	_	
16-12	3026-3029	hip	_	_	
16-13	3030-3035	joint	_	_	
16-14	3036-3050	endoprostheses	_	_	
16-15	3050-3051	.	_	_	

#Text=A colonization with vital body cells promotes the integration of the implant and impedes an infection.
#Text=[0004] Therefore it is an object of the present invention to provide a coating for implants which inhibits the growth of introduced microorganisms on these implants, particularly the growth of bacteria, and which subsequently provides a biocompatible surface for the body's own cells.
17-1	3052-3053	A	_	_	
17-2	3054-3066	colonization	_	_	
17-3	3067-3071	with	_	_	
17-4	3072-3077	vital	_	_	
17-5	3078-3082	body	_	_	
17-6	3083-3088	cells	_	_	
17-7	3089-3097	promotes	_	_	
17-8	3098-3101	the	_	_	
17-9	3102-3113	integration	_	_	
17-10	3114-3116	of	_	_	
17-11	3117-3120	the	_	_	
17-12	3121-3128	implant	_	_	
17-13	3129-3132	and	_	_	
17-14	3133-3140	impedes	_	_	
17-15	3141-3143	an	_	_	
17-16	3144-3153	infection	_	_	
17-17	3153-3154	.	_	_	
17-18	3155-3156	[	_	_	
17-19	3156-3160	0004	_	_	
17-20	3160-3161	]	_	_	
17-21	3162-3171	Therefore	_	_	
17-22	3172-3174	it	_	_	
17-23	3175-3177	is	_	_	
17-24	3178-3180	an	_	_	
17-25	3181-3187	object	_	_	
17-26	3188-3190	of	_	_	
17-27	3191-3194	the	_	_	
17-28	3195-3202	present	_	_	
17-29	3203-3212	invention	_	_	
17-30	3213-3215	to	_	_	
17-31	3216-3223	provide	_	_	
17-32	3224-3225	a	_	_	
17-33	3226-3233	coating	_	_	
17-34	3234-3237	for	_	_	
17-35	3238-3246	implants	_	_	
17-36	3247-3252	which	_	_	
17-37	3253-3261	inhibits	_	_	
17-38	3262-3265	the	_	_	
17-39	3266-3272	growth	_	_	
17-40	3273-3275	of	_	_	
17-41	3276-3286	introduced	_	_	
17-42	3287-3301	microorganisms	_	_	
17-43	3302-3304	on	_	_	
17-44	3305-3310	these	_	_	
17-45	3311-3319	implants	_	_	
17-46	3319-3320	,	_	_	
17-47	3321-3333	particularly	_	_	
17-48	3334-3337	the	_	_	
17-49	3338-3344	growth	_	_	
17-50	3345-3347	of	_	_	
17-51	3348-3356	bacteria	_	_	
17-52	3356-3357	,	_	_	
17-53	3358-3361	and	_	_	
17-54	3362-3367	which	_	_	
17-55	3368-3380	subsequently	_	_	
17-56	3381-3389	provides	_	_	
17-57	3390-3391	a	_	_	
17-58	3392-3405	biocompatible	_	_	
17-59	3406-3413	surface	_	_	
17-60	3414-3417	for	_	_	
17-61	3418-3421	the	_	_	
17-62	3422-3428	body's	_	_	
17-63	3429-3432	own	_	_	
17-64	3433-3438	cells	_	_	
17-65	3438-3439	.	_	_	
